10-Q: ORIC Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

ORIC Pharmaceuticals reports a net loss of $30.0 million for Q1 2025 and provides updates on its clinical programs, including ORIC-944 and ORIC-114.

Summary

• ORIC Pharmaceuticals, a clinical-stage biopharmaceutical company, announced its financial results for the first quarter ended March 31, 2025.
• The company reported a net loss of $30.0 million, compared to a net loss of $25.0 million for the same period in 2024.
• Research and development expenses increased to $24.6 million from $22.0 million in the prior year, driven by the advancement of ORIC-944 and ORIC-114.
• General and administrative expenses rose to $8.1 million from $7.0 million, primarily due to higher personnel costs.
• The company's cash, cash equivalents, and investments totaled $223.8 million as of March 31, 2025.
• ORIC Pharmaceuticals believes its current financial resources will be sufficient to fund operations into 2027.
• The company is advancing its clinical-stage product candidates, ORIC-944 and ORIC-114, and expects to initiate a Phase 3 trial for ORIC-944 in metastatic castration-resistant prostate cancer (mCRPC) in the first half of 2026.
• A comprehensive data update for ORIC-114 is expected in the second half of 2025, and Phase 3 trials for ORIC-114 in first-line non-small cell lung cancer (NSCLC) are expected to begin in 2026.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company has a solid cash position and is advancing its clinical programs, it is also experiencing increasing losses and faces significant risks and uncertainties. The sentiment is neutral, reflecting the inherent challenges and opportunities in the biopharmaceutical industry.

Positives

• The company believes its current cash, cash equivalents and investments will be sufficient to fund its current operating plan into 2027.
• ORIC is advancing its clinical programs for ORIC-944 and ORIC-114, with Phase 3 trials anticipated in the near future.
• The company has entered into clinical trial collaboration and supply agreements with Johnson & Johnson and Bayer to evaluate ORIC-944 in combination with their respective androgen receptor inhibitors.

Negatives

• ORIC Pharmaceuticals reported a net loss of $30.0 million for the first quarter of 2025, an increase from the $25.0 million loss in the same period of 2024.
• The company has an accumulated deficit of $592.8 million as of March 31, 2025.
• ORIC has not generated any revenue from product sales to date and does not anticipate generating any meaningful revenue in the near term.

Risks

• The company's future success is highly dependent on the successful development and commercialization of its product candidates, particularly ORIC-944 and ORIC-114.
• Clinical trials may not demonstrate the safety and efficacy of the company's product candidates.
• The company faces significant competition in the biotechnology and pharmaceutical industries.
• The company relies on third-party manufacturers and suppliers, and any disruptions in these relationships could harm its business.
• The company may be unable to obtain regulatory approval for its product candidates.
• The company may be unable to obtain adequate reimbursement for its product candidates, if approved.
• The company may be subject to product liability claims.
• The company may be unable to protect its intellectual property rights.
• The company may need to raise additional capital in the future, and such capital may not be available on acceptable terms or at all.

Future Outlook

ORIC Pharmaceuticals expects its current cash, cash equivalents, and investments will be sufficient to fund its current operating plan into 2027 and plans to initiate a Phase 3 trial for ORIC-944 in mCRPC in the first half of 2026, with Phase 3 trials for ORIC-114 in first-line NSCLC planned for 2026.

Management Comments

• Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date of the issuance of these financial statements.

Industry Context

ORIC Pharmaceuticals is operating in the competitive biopharmaceutical industry, focusing on oncology. The company is developing therapies to counter resistance mechanisms in cancer, specifically in hormone-dependent cancers, precision oncology, and key tumor dependencies. The company faces competition from major pharmaceutical companies, established biotechnology companies, and emerging companies.

Comparison to Industry Standards

• It's difficult to directly compare ORIC's results to industry standards without knowing the specific stage and focus of comparable companies.
• However, ORIC's Q1 2025 R&D expenses of $24.6 million are within the range of other clinical-stage biotech companies.
• For example, companies like Mirati Therapeutics (now acquired by Bristol Myers Squibb) and Voronoi Inc., from whom ORIC licensed key assets, also invested heavily in R&D during their clinical stages.
• ORIC's cash runway into 2027 is a positive sign, as many biotech companies face funding challenges.
• However, the company's increasing net loss and accumulated deficit highlight the need for successful clinical trial outcomes and potential commercialization to achieve profitability.
• Companies like Exelixis and Incyte, which successfully commercialized oncology drugs, serve as benchmarks for ORIC's long-term goals.

Legal Proceedings

• The SEC filed a civil enforcement action against ORIC's Chief Business Officer for insider trading in violation of the securities laws, involving transactions that occurred in 2016 while the officer was employed by a different company.
• On April 5, 2024, a jury found the Chief Business Officer liable for insider trading.
• Pursuant to the final judgment entered by the Court on October 24, 2024, the Chief Business Officer is subject to a monetary penalty and is permanently enjoined from violating Section 10(b) of the Exchange Act and Rule 10b-5 promulgated thereunder but is not in any way prohibited or enjoined from serving as an officer or director of a public company.
• The Chief Business Officer has appealed the decision to the Ninth Circuit Court of Appeals.

Stakeholder Impact

• Shareholders: The company's financial performance and clinical trial progress will directly impact shareholder value.
• Employees: The company's ability to attract and retain talent is crucial for its success.
• Patients: The development of new therapies could provide significant benefits to patients with cancer.
• Suppliers: The company's relationships with third-party manufacturers and suppliers are essential for its operations.
• Creditors: The company's financial stability and ability to raise capital are important for its creditors.

Next Steps

• Report dose escalation data of ORIC-944 both in combination with apalutamide and in combination with darolutamide in the first half of 2025.
• Provide an additional update on ORIC-944 data in the second half of 2025.
• Report dose optimization data in combination with AR inhibitor(s) in the fourth quarter of 2025 or first quarter of 2026 for ORIC-944.
• Initiate the first Phase 3 trial for ORIC-944 in mCRPC in the first half of 2026.
• Provide a comprehensive data update for ORIC-114 during the second half of 2025.
• Initiate Phase 3 trial(s) for ORIC-114 in first-line NSCLC in 2026.

Key Dates

Keywords

ORIC Pharmaceuticals, ORIC-944, ORIC-114, Clinical trials, Financial results, mCRPC, NSCLC, Research and development, Biopharmaceutical, Oncology